

Fig. 15 HbA1c




Fig. 16 WBC




Fig. 17 RBC




Fig. 18 Hemoglobin




Fig. 19 Hematocrit





Fig. 20 Platelet



検査成績報告書 告書 告書

3389(2377) 津健康クリニック 津健康クリニック 津健康クリニック

277
087

男性
49才

Male
KM 49

コメント 混濁(1+) コメント

11/03/02 11/03/16 11/03/30 11/03/31

Serum Total protein

Albumin

Total cholesterol

Triglyceride

BUN

Creatinine

Uric acid

WBC

RBC

Hemoglobin

Hematocrit

Platelet

検査項目	測定値	測定値	測定値	単位	基準値
★血清総蛋白	7.3	7.1	7.1	g/dl	6.5~8.2
★A/G比	1.3	1.4	1.4		1.1~2.0
★アルブミン	4.1	4.1	4.1	g/dl	3.7~5.3
★ZTT	3.3	4.2	4.7	units	3.0~12.0
★ALP	362	353	367	IU/l	100~350
★LAP	67	68	59	IU/l	35~75
★GOT	20	25	19	IU/l	10~40
★GPT	22	26	27	IU/l	6~40
★LDH	301	291	284	IU/l	230~460
★γ-GTP	25	20	20	IU/l	50以下
★総コレステロール	178	132	172	mg/dl	130~220
★トリグリセライド	74	89	200	mg/dl	35~150
★尿素窒素	15	17	15	mg/dl	8~21
★クレアチニン	0.8	0.9	0.7	mg/dl	0.6~1.3
★尿酸	4.4	4.5	4.5	mg/dl	2.5~7.5
★Hb-A1c	5.7		5.2	%	4.3~5.8
★白血球数	58	472	72	×10 ⁴ /μl	36~92
★赤血球数	572	12.6	564	×10 ⁴ /μl	420~560
★ヘモグロビン量	15.9	41.5	16.1	g/dl	13.0~17.0
★ヘマトクリット値	49.7	88	49.3	%	39.0~50.0
MCV	87	26.7	87	f l	81~98
MCH	27.8	30.4	28.5	pg	27.0~33.0
MCHC	32.0	21.6	32.7	%	32.0~35.0
★血小板数	25.2		24.2	×10 ⁴ /μl	14.0~35.0
		0.0			
		0.0	0.0	%	0.0
		42.5	0.0	%	0.0
		3.9	52.3	%	36.0~69.0
		1.1	4.1	%	1.0~5.0
		45.8	0.7	%	0.0~2.0
		0.0	37.9	%	27.0~53.0
		6.7	0.0	%	0.0
			5.0	%	2.0~10.0

総合報告書 I 11/03/02 11/03/16 11/03/30 11/03/31

登録衛生検査 登録衛生検査 登録衛生検査所 実施料 329点

大谷 敦 (株)メディック (株)メディック (株)メディック

TEL(059)2 TEL(059)2 TEL(059)224-5455

検査成績報告書

検査成績報告 検査成績報告 検査成績報告書

津健康クリニック 津健康クリニック 津健康クリニック

様 3389(2377)

3389(2377) 津健康クリニック

男性 50才

実施料 329点 実施料 244点 実施料 329点

IDNo 2-77009 IDNo 2-77082 IDNo 2-77092

受付11/04/13 受付11/04/27 受付11/05/11 受付11/05/25

報告11/05/26 採取

検査項目	測定値	測定値	測定値	測定値	単位	基準値	検査項目
★血清総蛋白	7.1	7.6	7.0	7.2	g/dl	6.5~8.2	*血清総蛋白
★A/G比	1.4	1.3	1.4	1.5		1.1~2.0	*A/G比
★アルブミン	4.2	4.3	4.1	4.3	g/dl	3.7~5.3	*アルブミン
★ZTT	3.7	3.3	4.1	3.7	units	3.0~12.0	*ZTT
★ALP	324	419	352	324	IU/l	100~350	*ALP
★LAP	65	62	63	65	IU/l	35~75	*LAP
★GOT	19	21	27	21	IU/l	10~40	*GOT
★GPT	21	24	25	26	IU/l	6~40	*GPT
★LDH	291	310	286	293	IU/l	230~460	*LDH
★γ-GTP	17	21	23	23	IU/l	50以下	*γ-GTP
★総コレステロール	166	187	184	177	mg/dl	130~220	*総コレステロール
★トリグリセライド	79	105	123	98	mg/dl	35~150	*トリグリセライド
★尿素窒素	17	19	17	16	mg/dl	8~21	*尿素窒素
★クレアチニン	0.9	0.9	0.7	0.7	mg/dl	0.6~1.3	*クレアチニン
★尿酸	4.9	5.6	5.6	4.8	mg/dl	2.5~7.5	*尿酸
		5.6	79	91	mg/dl	70~110	*血糖
★白血球数	63			5.3	%	4.3~5.8	*Hb-A1c
★赤血球数	537	79	61				
★ヘモグロビン量	15.4	570	553	61	×10 ⁹ /μl	36~92	*白血球数
★ヘマトクリット値	46.9	16.3	15.7	568	×10 ⁹ /μl	420~560	*赤血球数
MCV	87	49.5	47.9	16.2	g/dl	13.0~17.0	*ヘモグロビン量
MCH	28.7	87	87	48.8	%	39.0~50.0	*ヘマトクリット値
MCHC	32.8	28.6	28.4	86	f l	81~98	MCV
★血小板数	22.6	32.9	32.8	28.5	pg	27.0~33.5	MCH
★血液像		23.1	22.9	33.2	%	32.0~35.0	MCHC
骨髄球	0.0			23.6	×10 ⁴ /μl	14.0~35.0	*血小板数
後骨髄球	0.0	0.0	0.0				*血液像
好中球	52.3	0.0	0.0	0.0	%	0.0	骨髄球
好酸球	3.8	54.8	51.4	0.0	%	0.0	後骨髄球
好塩基球	1.0	3.9	4.6	51.9	%	36.0~69.0	好中球
リンパ球	37.6	1.0	1.3	4.4	%	1.0~5.0	好酸球
異型リンパ球	0.0	35.4	37.5	1.1	%	0.0~2.0	好塩基球
単球	5.3	0.0	0.0	35.4	%	27.0~53.0	リンパ球
大小不同		4.9	5.2	0.0	%	0.0	異型リンパ球
環状				7.2	%	2.0~10.0	単球
奇形							大小不同
赤芽球							環状
							奇形
							赤芽球

総合報告書I 11/04/13 受付11/04/27 受付11/05/11 受付11/05/25 報告11/05/26 総合報告書I

登録衛生検査所 (株)メデイック TEL(059)2
 登録衛生検査所 (株)メデイック TEL(059)2
 登録衛生検査所 (株)メデイック TEL(059)224-5455
 責任者 大谷 教

検査成績報告書

クリニック 3389(2377) 津健康クリニック 健康クリニック

277
088

男性
67才

Male
KS 67

コメト 混濁 (2+) 小 混濁 (1+)

03/02 検査 11/03/16 11/03/30 11/03/31

定値	検査項目	測定値	測定値	単位	基準値
Serum total protein 8.1	★血清総蛋白	7.6	7.4	g/dl	6.5~8.2
Albumin 1.3	★A/G比	1.2	1.4		1.1~2.0
4.6	★アルブミン	4.0	4.3	g/dl	3.7~5.3
4.8	★ZTT	6.5	5.8	units	3.0~12.0
309	★ALP	279	273	IU/l	100~350
76	★LAP	65	58	IU/l	35~75
35	★GOT	22	25	IU/l	10~40
52	★GPT	29	33	IU/l	6~40
354	★LDH	333	320	IU/l	230~460
69	★γ-GTP	53	56	IU/l	50以下
Total cholesterol 292	★総コレステロール	270	270	mg/dl	130~220
Triglyceride 374	★トリグリセライド	580	387	mg/dl	35~150
BUN 17	★尿素窒素	17	20	mg/dl	8~21
Creatinine 1.1	★クレアチニン	1.3	1.1	mg/dl	0.6~1.3
Uric acid 6.4	★尿酸	6.0	6.9	mg/dl	2.5~7.5
6.9	★Hb-A1C	62	119	mg/dl	70~110
			6.3	%	4.3~5.8
WBC 54	★白血球数	516			
RBC 518	★赤血球数	15.0	51	×10 ⁹ /μl	36~92
Homoglobin 15.2	★ヘモグロビン量	48.6	513	×10 ⁴ /μl	420~560
Hematocrit 47.9	★ヘマトクリット値	94	15.4	g/dl	13.0~17.0
92	MCV	29.1	47.7	%	39.0~50.0
29.3	MCH	30.9	93	f l	81~98
31.7	MCHC	24.7	30.0	pg	27.0~33.5
Platelet 25.7	★血小板数	0.0	32.3	%	32.0~35.0
		0.0	24.8	×10 ⁴ /μl	14.0~35.0
		51.5	0.0	%	0.0
		1.4	0.0	%	0.0
		1.1	47.7	%	36.0~69.0
		42.6	2.2	%	1.0~5.0
		0.0	1.4	%	0.0~2.0
		3.4	45.7	%	27.0~53.0
			0.0	%	0.0
			3.0	%	2.0~10.0

703/02

総合報告書 I

11/03/16

11/03/30

11/03/31

録衛生検査所

登録衛生検査

登録衛生検査所

実施料 329点

ディック

大谷 教

(株)メディック (株)メディック

TEL(059)22

大谷 教

TEL(059)2

TEL(059)224-5455

検査成績報告書

検査成績報告書 検査成績報告 検査成績報告 検査成績報告書

3389(2377) 津健康クリニック 津健康クリニック 3389(2377) 津健康クリニック 様

3389(2377) 津健康クリニック 様 男性 67才

実施料 329点 実施料 244点 実施料 329点
 コント 混濁(2+) IDNo 2-77002 IDNo 2-77083 IDNo 2-77089
 番号 11/04/13 受付11/04/27 受付11/05/11 採取 受付11/05/25 報告11/05/26

検査項目	測定値	測定値	測定値	検査項目	測定値	単位	基準値
*血清総蛋白	7.1	7.6	7.2	*血清総蛋白	7.2	g/dl	6.5~8.2
*A/G比	1.4	1.3	1.4	*A/G比	1.5		1.1~2.0
*アルブミン	4.2	4.3	4.2	*アルブミン	4.3	g/dl	3.7~5.3
*ZTT	5.3	4.3	5.0	*ZTT	4.0	units	3.0~12.0
*ALP	273	256	246	*ALP	283	IU/l	100~350
*LAP	56	58	52	*LAP	53	IU/l	35~75
*GOT	19	25	17	*GOT	23	IU/l	10~40
*GPT	25	28	23	*GPT	27	IU/l	6~40
*LDH	289	326	329	*LDH	345	IU/l	230~460
*γ-GTP	41	42	30	*γ-GTP	31	IU/l	50以下
*総コレステロール	243	268	227	*総コレステロール	238	mg/dl	130~220
*トリグリセライド	378	369	190	*トリグリセライド	374	mg/dl	35~150
*尿素窒素	21	18	18	*尿素窒素	19	mg/dl	8~21
*クレアチニン	1.1	1.1	1.1	*クレアチニン	0.9	mg/dl	0.6~1.3
*尿酸	6.5	5.9	4.9	*尿酸	5.8	mg/dl	2.5~7.5
*血糖空腹時	113	99	102	*血糖	109	mg/dl	70~110
		6.9		*Hb-A1c	6.3	%	4.3~5.8
*白血球数	64		83	*白血球数	52	×10 ⁴ /μl	36~92
*赤血球数	513	51	518	*赤血球数	539	×10 ⁴ /μl	420~560
*ヘモグロビン量	15.6	15.7	15.7	*ヘモグロビン量	16.3	g/dl	13.0~17.0
*ヘマトクリット値	47.6	16.0	47.9	*ヘマトクリット値	49.3	%	39.0~50.0
MCV	93	49.7	92	MCV	91	fl	81~98
MCH	30.4	94	30.3	MCH	30.2	pg	27.0~33.5
MCHC	32.8	30.2	32.8	MCHC	33.1	%	32.0~35.0
*血小板数	22.8	32.2	25.8	*血小板数	23.5	×10 ⁴ /μl	14.0~35.0
*血液像		22.6		*血液像			
骨髄球	0.0		0.0	骨髄球	0.0	%	0.0
後骨髄球	0.0	0.0	0.0	後骨髄球	0.0	%	0.0
好中球	57.0	0.0	73.9	好中球	47.4	%	36.0~69.0
好酸球	1.7	46.3	0.2	好酸球	3.3	%	1.0~5.0
好塩基球	0.8	2.2	0.4	好塩基球	1.3	%	0.0~2.0
リンパ球	36.4	1.2	23.0	リンパ球	44.9	%	27.0~53.0
異型リンパ球	0.0	46.6	0.0	異型リンパ球	0.0	%	0.0
単球	4.1	0.0	2.5	単球	3.1	%	2.0~10.0
大小不同		3.7		大小不同			
環状				環状			
奇形				奇形			
赤芽球				赤芽球			

告書 告書

3389(2377) 津健康クリニック 津健康クリニック 津健康クリニック 277 082
 男性 49才
 Male
 H.N. ~~49~~ 49

11/03/02 11/03/16 11/03/30 11/03/31

検査項目	測定値	測定値	測定値	単位	基準値
Serum total protein	★血清総蛋白	8.2	8.1	8.0	g/dl 6.5~8.2
Albumin	★A/G比	1.1	1.3	1.2	1.1~2.0
	★アルブミン	4.2	4.5	4.4	g/dl 3.7~5.3
	★ZTT	5.9	7.0	7.2	units 3.0~12.0
	★ALP	188	186	177	IU/l 100~350
	★LAP	64	67	60	IU/l 35~75
	★GOT	25	23	20	IU/l 10~40
	★GPT	29	27	19	IU/l 6~40
	★LDH	403	371	395	IU/l 230~460
	★γ-GTP	25	21	18	IU/l 50以下
Total cholesterol	★総コレステロール	312	295	284	mg/dl 130~220
Triglyceride	★トリグリセライド	327	226	255	mg/dl 35~150
BUN	★尿素窒素	14	15	13	mg/dl 8~21
Creatinine	★クレアチニン	1.3	1.3	1.4	mg/dl 0.6~1.3
Uric acid	★尿酸	7.5	8.2	7.8	mg/dl 2.5~7.5
	★Hb-A1c	4.7	4.8	4.6	% 4.3~5.8
WBC	★白血球数	73	466	63	×10 ³ /μl 36~92
RBC	★赤血球数	550	13.7	547	×10 ⁴ /μl 420~560
Hemoglobin	★ヘモグロビン量	17.5	45.0	17.8	g/dl 13.0~17.1
Hematocrit	★ヘマトクリット値	52.2	97	52.7	% 39.0~50.1
	MCV	95	29.4	96	f l 81~98
	MCH	31.8	30.4	32.5	pg 27.0~33.1
	MCHC	33.5	19.3	33.8	% 32.0~35.1
Platelet	★血小板数	25.6	0.0	21.5	×10 ⁴ /μl 14.0~35.1
			0.0	0.0	% 0.0
			57.0	0.0	% 0.0
			3.1	59.6	% 36.0~69.
			0.6	2.5	% 1.0~5.0
			33.1	0.8	% 0.0~2.0
			0.0	32.5	% 27.0~53.
			6.2	0.0	% 0.0
				4.6	% 2.0~10.

検査成績報告書

検査成績報告書

検査成績報告書

3389(2377) 津健康クリニック

津健康クリニック 津健康クリニック

3389(2377) 津健康クリニック

様

男性 49才

実施料 329点 実施料 244点

実施料 329点

コメント 混濁(1+) IDNo 2-77085 IDNo 2-77084

IDNo 2-77087

11/04/14 受付 11/04/28 受付 11/05/12

11/05/26 報告 11/05/27

コメント

検査項目	測定値	測定値	測定値	検査項目	測定値	単位	基準値
★血清総蛋白	7.7	7.4	7.9	★血清総蛋白	7.9	g/dl	6.5~8.2
★A/G比	1.3	1.2	1.3	★A/G比	1.2		1.1~2.0
★アルブミン	4.3	4.0	4.4	★アルブミン	4.3	g/dl	3.7~5.3
★ZTT	7.5	7.3	7.2	★ZTT	7.3	units	3.0~12.0
★ALP	184	170	181	★ALP	178	IU/l	100~350
★LAP	60	59	62	★LAP	61	IU/l	35~75
★GOT	19	19	19	★GOT	18	IU/l	10~40
★GPT	21	22	17	★GPT	18	IU/l	6~40
★LDH	343	342	371	★LDH	366	IU/l	230~480
★γ-GTP	17	18	18	★γ-GTP	17	IU/l	50以下
★総コレステロール	↑ 264	↑ 263	↑ 283	★総コレステロール	↑ 285	mg/dl	130~220
★トリグリセライド	↑ 358	↑ 371	↑ 304	★トリグリセライド	↑ 332	mg/dl	35~150
★尿酸素素	16	14	15	★尿酸素素	16	mg/dl	8~21
★クレアチニン	1.5	1.4	1.4	★クレアチニン	1.2	mg/dl	0.6~1.3
★尿酸	7.7	8.6	8.2	★尿酸	8.1	mg/dl	2.5~7.5
		5.1		★Hb-A1c	4.8	%	4.3~5.8
★白血球数	71		72	★白血球数	67	×10 ³ /μl	38~92
★赤血球数	542	56	541	★赤血球数	541	×10 ⁴ /μl	420~560
★ヘモグロビン量	17.6	528	17.4	★ヘモグロビン量	17.4	g/dl	13.0~17.0
★ヘマトクリット値	51.8	17.1	51.7	★ヘマトクリット値	51.0	%	39.0~50.0
MCV	96	50.4	96	MCV	94	f l	81~98
MCH	32.5	95	32.2	MCH	32.2	pg	27.0~33.5
MCHC	34.0	32.4	33.7	MCHC	34.1	%	32.0~35.0
★血小板数	21.8	33.9	21.0	★血小板数	21.9	×10 ⁴ /μl	14.0~35.0
★血液像		21.3		★血液像			
骨髄球	0.0		0.0	骨髄球	0.0	%	0.0
後骨髄球	0.0	0.0	0.0	後骨髄球	0.0	%	0.0
好中球	63.9	0.0	64.2	好中球	56.5	%	38.0~69.0
好酸球	3.9	59.8	3.5	好酸球	3.9	%	1.0~5.0
好塩基球	0.8	4.8	1.0	好塩基球	1.0	%	0.0~2.0
リンパ球	27.3	0.7	26.4	リンパ球	34.6	%	27.0~53.0
異型リンパ球	0.0	29.4	0.0	異型リンパ球	0.0	%	0.0
単球	4.1	0.0	4.9	単球	4.0	%	2.0~10.0
大小不同		5.3		大小不同			
環状				環状			
奇形				奇形			
赤芽球				赤芽球			

総合報告書 I

11/04/14 受付 11/04/28 受付 11/05/12

総合報告書 I

11/05/26 報告 11/05/27

登録衛生検査所

登録衛生検査所

登録衛生検査所

登録衛生検査所

(株)メディック

(株)メディック

(株)メディック

責任者

(株)メディック

大谷 教

TEL(059)22

TEL(059)2

TEL(059):

大谷 教

TEL(059)224-5455

告書 告書

3389(2377) 津健康クリニック 津健康クリニック 津健康クリニック 277

081

男性

34才

Male
Y.I. 34

11/03/02 11/03/16 11/03/30 11/03/31

検査項目	測定値	測定値	測定値	単位	基準値
Serum total protein ★血清総蛋白	8.1	7.8	8.0	g/dl	6.5~8.2
Albumin ★A/G比	1.3	1.4	1.3		1.1~2.0
★アルブミン	4.6	4.5	4.5	g/dl	3.7~5.3
★ZTT	7.3	8.8	9.0	units	3.0~12.1
★ALP	246	248	247	IU/l	100~350
★LAP	85	81	76	IU/l	35~75
★GOT	26	20	17	IU/l	10~40
★GPT	41	33	26	IU/l	6~40
★LDH	366	429	391	IU/l	230~460
★γ-GTP	30	29	26	IU/l	50以下
★総コレステロール	223	202	220	mg/dl	130~220
★トリグリセライド	125	157	73	mg/dl	35~150
★尿素窒素	14	15	21	mg/dl	8~21
★クレアチニン	0.8	0.9	0.8	mg/dl	0.6~1.3
★尿酸	5.0	5.8	5.2	mg/dl	2.5~7.5
★Hb-A1C	4.9		4.7	%	4.3~5.8
★白血球数	56	65	76	×10 ³ /μl	36~92
★赤血球数	542	13.1	543	×10 ⁴ /μl	420~560
★ヘモグロビン量	15.1	42.8	15.5	g/dl	13.0~17.0
★ヘマトクリット値	46.8	89	47.8	%	39.0~50.0
MCV	86	27.1	88	f l	81~98
MCH	27.9	30.6	28.5	pg	27.0~33.0
MCHC	32.3	23.2	32.4	%	32.0~35.0
★血小板数	23.0	0.0	23.8	×10 ⁴ /μl	14.0~35.0
		0.0	0.0	%	0.0
		52.3	0.0	%	0.0
		6.3	60.9	%	36.0~69.0
		0.3	11.1	%	1.0~5.0
		36.1	0.8	%	0.0~2.0
		0.0	24.2	%	27.0~53.0
		5.0	0.0	%	0.0
			3.0	%	2.0~10.0

総合報告書 I 11/03/0 11/03/1 11/03/30 11/03/3

登録衛生検査所 登録衛生検査所 登録衛生検査所 登録衛生検査所 329

大谷 敦 (株)メディック (株)メディック (株)メディック

TEL(059)2 TEL(059)2 TEL(059)224-5455

検査成績報告

検査成績報告書

検査成績報告 検査成績報告 検査成績報告書

津健康クリニック 津健康クリニック 津健康クリニック

3389(2377)

津健康クリニック

様

男性 34才

実施料 329点 実施料 244点 実施料 329点

コメント

IDNo 2-77001 IDNo 2-77081 IDNo 2-77091

コ乳腺
レント
ゲン

受取

受付

11/04/13

11/04/27

11/05/11

11/05/25

報告11/05/26

検査項目	測定値	測定値	測定値	測定値	単位	基準値
★血清総蛋白	7.8	7.7	7.5	8.0	g/dl	6.5~8.2
★A/G比	1.4	1.2	1.3	1.2		1.1~2.0
★アルブミン	4.5	4.2	4.2	4.3	g/dl	3.7~5.3
★ZTT	9.7	9.6	9.8	10.8	units	3.0~12.0
★ALP	232	238	234	243	IU/l	100~350
★LAP	81	75	80	73	IU/l	35~75
★GOT	21	22	20	16	IU/l	10~40
★GPT	39	38	36	22	IU/l	6~40
★LDH	356	370	377	385	IU/l	230~460
★γ-GTP	28	32	35	26	IU/l	50以下
★総コレステロール	202	204	211	202	mg/dl	130~220
★トリグリセライド	111	159	139	428	mg/dl	35~150
★尿素窒素	19	21	25	14	mg/dl	8~21
★クレアチニン	0.9	0.9	0.9	0.8	mg/dl	0.6~1.3
★尿酸	5.7	5.2	6.5	5.8	mg/dl	2.5~7.5
		5.3		4.8	%	4.3~5.8
★白血球数	65		74			
★赤血球数	556	67	504	72	×10 ⁹ /μl	36~92
★ヘモグロビン量	15.7	525	14.3	523	×10 ⁹ /μl	420~560
★ヘマトクリット値	48.4	15.0	43.8	15.0	g/dl	13.0~17.0
MCV	87	45.9	87	45.1	%	39.0~50.0
MCH	28.2	87	28.4	86	f/l	81~98
MCHC	32.4	28.6	32.6	28.7	pg	27.0~33.5
★血小板数	23.3	32.7	22.3	33.3	%	32.0~35.0
★血液像		22.7		25.7	×10 ⁴ /μl	14.0~35.0
骨髄球	0.0		0.0			
後骨髄球	0.0	0.0	0.0	0.0	%	0.0
好中球	54.0	0.0	64.8	0.0	%	0.0
好酸球	9.4	61.4	4.6	62.3	%	36.0~69.0
好塩基球	0.8	5.4	0.5	4.7	%	1.0~5.0
リンパ球	31.3	0.8	27.7	0.4	%	0.0~2.0
異型リンパ球	0.0	27.6	0.0	28.7	%	27.0~53.0
単球	4.5	0.0	2.4	0.0	%	0.0
大小不同		4.8		3.9	%	2.0~10.0
環状						
奇形						
赤芽球						

総合報告書 I

11/04/13 受付 11/04/27 受付 11/05/11 受付 11/05/25 報告 11/05/26

登録衛生検査所

登録衛生検査

登録衛生検査

登録衛生検査所

〒

(株)メディック

(株)メディック

(株)メディック

(株)メディック

大谷 数

TEL(059)22

TEL(059)22

TEL(059)22

TEL(059)224-5455

検査成績報告書

3389(2377) 津健康クリニック 津健康クリニック 津健康クリニック

ICNo
290
350
女性

Final
A.M 33

検査項目	測定値	測定値	測定値	単位	基準値
Serum total protein	7.7	7.6	7.4	g/dl	6.5~8.2
Albumin	4.3	4.3	4.3	g/dl	3.7~5.3
	7.6	11.0	9.8	units	3.0~12.0
	188	170	176	IU/l	100~350
	52	57	49	IU/l	35~75
	14	15	11	IU/l	10~40
	12	16	11	IU/l	6~40
	268	262	264	IU/l	230~460
	15	14	14	IU/l	50以下
Total cholesterol	221	236	178	mg/dl	130~220
Triglyceride	80	135	130	mg/dl	35~150
BUN	15	15	13	mg/dl	8~21
Creatinine	0.9	1.0	0.9	mg/dl	0.6~1.3
Uric acid	5.6	5.2	5.3	mg/dl	2.0~6.5
	4.5		4.5	%	4.3~5.8
WBC	56	59	57	$\times 10^4/\mu l$	36~92
RBC	513	11.9	491	$\times 10^4/\mu l$	380~500
Hemoglobin	14.9	38.7	14.1	g/dl	11.2~14.7
Hematocrit	46.8	94	44.7	%	33.5~43.5
	91	28.8	91	f l	81~98
	29.0	30.7	28.7	pg	27.0~33.5
	31.8	24.4	31.5	%	32.0~35.0
Platelet	32.7		31.4	$\times 10^4/\mu l$	14.0~35.0
		0.0			
		0.0	0.0	%	0.0
		57.9	0.0	%	0.0
		5.4	46.2	%	36.0~69.0
		1.0	5.7	%	1.0~5.0
		29.0	0.7	%	0.0~2.0
		0.0	40.8	%	27.0~53.0
		6.7	0.0	%	0.0
			6.6	%	2.0~10.0

総合報告書 I 11/03/0 11/03/1 11/03/30 11/03/31
 登録衛生検査所 登録衛生検査所 登録衛生検査所 実施料 329点
 (株)メデイック (株)メデイック (株)メデイック
 大谷 敦 TEL(059)2 TEL(059)2 TEL(059)224-5455

389(2377)

検査成績クリニック

検査成績クリニック

検査成績クリニック

検査成績クリニック

CONFIDENTIAL
女性 33才

実施料 329点

実施料 244点

実施料 329点

IDNo 2-77086

IDNo 2-90350

IDNo 2-77088

11/04/13 受付 11/04/28

11/05/12 受付 11/05/28

報告 11705729

項目	11/04/13	11/04/28	11/05/12	11/05/28	単位	参考値
血清総蛋白	7.6	7.4	7.3	7.5	g/dl	6.5~8.2
A/G比	1.3	1.2	1.3	1.2		1.1~2.0
アルブミン	4.3	4.1	4.1	4.1	g/dl	3.7~5.3
ZTT	8.9	9.5	8.7	9.7	units	3.0~12.0
ALP	169	156	169	172	U/l	100~350
LAP	54	49	52	54	U/l	35~75
GOT	15	15	16	16	U/l	10~40
GPT	15	16	17	19	U/l	6~40
LDH	293	278	290	257	U/l	230~460
ア-GTP	14	16	14	12	U/l	60以下
総コレステロール	193	191	189	179	mg/dl	130~220
トリグリセライド	109	95	95	95	mg/dl	35~150
尿尿酸	18	14	14	11	mg/dl	8~21
クレアチニン	1.1	1.0	1.0	1.0	mg/dl	0.8~1.3
尿酸	6.4	5.7	5.0	4.8	mg/dl	2.0~6.5
		5.0		4.4	%	4.3~5.8
白血球数	94		75			
赤血球数	480	46	473	52	$\times 10^9/\mu l$	38~93
ヘモグロビン量	14.8	468	14.3	468	$\times 10^9/\mu l$	380~500
ヘマトクリット値	43.5	14.2	43.4	14.1	g/dl	11.2~14.7
MCV	91	42.6	92	42.5	%	33.5~43.5
MCH	30.8	91	30.2	91	f2	61~88
MCHC	34.0	30.3	32.9	30.1	%	27.0~33.5
血小板数	28.8	33.3	22.8	33.2	%	32.0~35.0
血沈速		28.3		24.3	$\times 10^9/\mu l$	14.0~35.0
骨髄球	0.0		0.0			
骨髄球	0.0	0.0	0.0	0.0	%	0.0
好中球	59.3	0.0	61.8	0.0	%	0.0
好酸球	5.2	45.2	5.1	52.4	%	36.0~88.0
好塩基球	0.5	6.8	0.1	5.2	%	1.0~5.0
リンパ球	29.8	1.1	27.1	1.0	%	0.0~2.0
異型リンパ球	0.0	41.2	0.0	37.7	%	27.0~53.0
異球	5.2	0.0	5.9	0.0	%	0.0
大小不同		5.7		3.7	%	2.0~10.0
塵状						
奇形						
赤芽球						

総合報告書 | 11/04/13 受付 11/04/28 | 11/05/12 受付 11/05/28 | 報告 11705729

検査成績クリニック (株)メディック TEL(059)224-5455
 検査成績クリニック (株)メディック TEL(059)2
 検査成績クリニック (株)メディック TEL(059)2
 検査成績クリニック (株)メディック TEL(059)2

検査成績報告書 告書 告書

3389(2377) 津健康クリニック 津健康クリニック 津健康クリニック
 IDNo 277
 091
 女性
 65才

Final K.S. ES

11/03/03 11/03/17 11/04/01 11/04/02

検査項目	測定値	測定値	測定値	単位	基準値
Serum total protein	7.4	7.7	7.4	g/dl	6.5~8.2
Albumin	1.6	1.5	1.6		1.1~2.0
★アルブミン	4.5	4.6	4.5	g/dl	3.7~5.3
★ZTT	6.6	6.1	6.6	units	3.0~12.0
★ALP	374	417	360	IU/l	100~350
★LAP	56	55	52	IU/l	35~75
★GOT	23	20	25	IU/l	10~40
★GPT	19	15	17	IU/l	6~40
★LDH	357	317	372	IU/l	230~460
★γ-GTP	14	14	12	IU/l	50以下
Total cholesterol	209	214	173	mg/dl	130~220
Triglyceride	206	193	72	mg/dl	35~150
BUN	11	15	17	mg/dl	8~21
★クレアチニン	0.5	0.4	0.5	mg/dl	0.6~1.3
Uric acid	4.9	5.4	4.6	mg/dl	2.0~6.5
★Hb-A1c	5.5		5.4	%	4.3~5.8
WBC	50	53	43	×10 ³ /μl	36~92
RBC	426	442	407	×10 ⁴ /μl	380~500
Hemoglobin	12.9	42.4	12.6	g/dl	11.2~14.7
Hematocrit	40.4	96	39.8	%	33.5~43.5
MCV	95	30.8	98	f l	81~98
MCH	30.3	32.1	31.0	pg	27.0~33.5
MCHC	31.9	27.1	31.7	%	32.0~35.0
Platelet	26.2		24.7	×10 ⁴ /μl	14.0~35.0
		0.0			
		0.0	0.0	%	0.0
		63.9	0.0	%	0.0
		1.9	43.9	%	36.0~69.0
		0.2	1.6	%	1.0~5.0
		26.3	0.7	%	0.0~2.0
		0.0	49.3	%	27.0~53.0
		7.7	0.0	%	0.0
			4.5	%	2.0~10.0

検査成績報告書

3389(2377) 津健康クリニック 津健康クリニック 3389(2377) 津健康クリニック 様

女性 65才

実施料 329点 実施料 244点 実施料 329点

コメント 11/04/14 受付 11/04/28 受付 11/05/11 IDNo 2-77082 IDNo 2-77085 IDNo 2-77084 報告 11/05/27

検査項目	測定値	測定値	測定値	検査項目	測定値	単位	基準値
★血清総蛋白	8.1	8.1	7.2	*血清総蛋白	7.6	g/dl	6.5~8.2
★A/G比	1.3	1.4	1.5	*A/G比	1.5		1.1~2.0
★アルブミン	4.6	4.7	4.3	*アルブミン	4.5	g/dl	3.7~5.3
★ZTT	6.6	6.6	6.4	*ZTT	5.4	units	3.0~12.0
★ALP	410	393	348	*ALP	368	IU/l	100~350
★LAP	57	57	54	*LAP	56	IU/l	35~75
★GOT	25	23	23	*GOT	25	IU/l	10~40
★GPT	20	19	19	*GPT	20	IU/l	6~40
★LDH	354	323	300	*LDH	393	IU/l	230~460
★γ-GTP	14	15	26	*γ-GTP	10	IU/l	50以下
★総コレステロール	228	222	216	*総コレステロール	185	mg/dl	130~220
★トリグリセライド	195	207	197	*トリグリセライド	150	mg/dl	35~150
★尿素窒素	17	14	13	*尿素窒素	17	mg/dl	8~21
★クレアチニン	0.6	0.6	0.6	*クレアチニン	0.5	mg/dl	0.6~1.3
★尿酸	5.4	5.7	4.8	*尿酸	4.6	mg/dl	2.0~6.5
		5.3		*Hb-A1c	5.2	%	4.3~5.8
★白血球数	43		37	*白血球数	39	×10 ⁹ /μl	36~92
★赤血球数	451	40	422	*赤血球数	440	×10 ⁹ /μl	380~500
★ヘモグロビン量	13.9	450	13.3	*ヘモグロビン量	13.7	g/dl	11.2~14.7
★ヘマトクリット値	43.0	14.1	39.8	*ヘマトクリット値	42.4	%	33.5~43.5
MCV	95	42.4	94	*MCV	96	f l	81~98
MCH	30.8	94	31.5	*MCH	31.1	pg	27.0~33.5
MCHC	32.3	31.3	33.4	*MCHC	32.3	%	32.0~35.0
★血小板数	26.1	33.3	24.4	*血小板数	26.5	×10 ⁴ /μl	14.0~35.0
★血液像		25.8		*血液像			
骨髄球	0.0		0.0	骨髄球	0.0	%	0.0
後骨髄球	0.0	0.0	0.0	後骨髄球	0.0	%	0.0
桿状核		0.0	33.6	好中球	36.6	%	36.0~69.0
分葉核		42.9	2.5	好酸球	3.4	%	1.0~5.0
好酸球	2.3	2.5	0.5	好塩基球	0.3	%	0.0~2.0
好塩基球	0.7	0.2	60.9	リンパ球	55.3	%	27.0~53.0
リンパ球	58.1	52.4	0.0	異型リンパ球	0.0	%	0.0
異型リンパ球	0.0	0.0	2.5	単球	4.4	%	2.0~10.0
単球	2.1	2.0		大小不同			
大小不同				環状			
環状				奇形			
奇形				赤芽球			
赤芽球							

検査成績報告書

告書

告書

3389(2377)

津健康クリニック

津健康クリニック

津健康クリニック

277
073

女性
42才

Frenal S.H 42

コメント

コメント

コメント

11/03/03 11/03/17 11/03/31 11/04/01

検査項目	測定値	測定値	測定値	単位	基準値
Serum total protein	7.4	7.5	7.6	g/dl	6.5~8.2
★血清総蛋白					
★A/G比	1.3	1.3	1.3		1.1~2.0
Albumin	4.2	4.3	4.3	g/dl	3.7~5.3
★アルブミン					
★ZTT	4.6	6.0	5.1	units	3.0~12.0
★ALP	213	203	174	IU/l	100~350
★LAP	45	47	46	IU/l	35~75
★GOT	18	20	20	IU/l	10~40
★GPT	16	23	21	IU/l	6~40
★LDH	279	274	277	IU/l	230~460
★γ-GTP	14	17	15	IU/l	50以下
Total cholesterol	215	181	207	mg/dl	130~220
★総コレステロール					
Triglyceride	199	156	201	mg/dl	35~150
★トリグリセライド					
★尿素窒素	12	14	16	mg/dl	8~21
★クレアチニン	0.7	0.8	0.7	mg/dl	0.6~1.3
★尿酸	3.4	4.2	4.2	mg/dl	2.0~6.5
★Hb-A1c	5.0		4.8	%	4.3~5.8
WBC	59	71	70	×10 ⁹ /μl	36~92
★白血球数					
RBC	426	425	416	×10 ⁴ /μl	380~500
★赤血球数					
Hemoglobin	13.1	40.9	13.0	g/dl	11.2~14.7
★ヘモグロビン量					
Hematocrit	40.3	96	40.2	%	33.5~43.5
★ヘマトクリット値					
MCV	95	30.1	97	f l	81~98
MCH	30.8	31.3	31.3	pg	27.0~33.5
MCHC	32.5	24.4	32.3	%	32.0~35.0
★血小板数	28.1		28.2	×10 ⁴ /μl	14.0~35.0
		0.0			
		0.0	0.0	%	0.0
		61.6	0.0	%	0.0
		2.2	54.4	%	36.0~69.0
		0.6	4.6	%	1.0~5.0
		30.8	1.0	%	0.0~2.0
		0.0	35.6	%	27.0~53.0
		4.8	0.0	%	0.0
			4.4	%	2.0~10.0

総合報告書 I 11/03/03 11/03/17 11/03/31 11/04/01

登録衛生検査所 登録衛生検査所 登録衛生検査所 実施料 329点

(株)メディック (株)メディック (株)メディック

大谷 教 TEL(059)24... TEL(059)24... TEL(059)224-5455

検査成績報告書

検査成績報告書

津健康クリニック 津健康クリニック 3389(2377) 津健康クリニック

3389(2377) 津健康クリニック

様

女性 42才

実施料 329点 実施料 244点

実施料 329点

IDNo 2-77083 IDNo 2-77083

IDNo 2-77088

採取 11/04/14 受付 11/04/28 受付 11/05/12

採取 11/05/26 報告 11/05/27

検査項目	測定値	測定値	測定値	検査項目	測定値	単位	基準値
★血清総蛋白	7.3	7.2	7.0	★血清総蛋白	7.3	g/dl	6.5~8.2
★A/G比	1.4	1.3	1.3	★A/G比	1.3		1.1~2.0
★アルブミン	4.2	4.1	4.0	★アルブミン	4.1	g/dl	3.7~5.3
★ZTT	5.6	5.1	5.5	★ZTT	4.9	units	3.0~12.0
★ALP	159	194	187	★ALP	157	IU/l	100~350
★LAP	43	45	43	★LAP	43	IU/l	35~75
★GOT	22	21	17	★GOT	16	IU/l	10~40
★GPT	17	24	20	★GPT	13	IU/l	6~40
★LDH	322	336	296	★LDH	309	IU/l	230~460
★γ-GTP	14	13	16	★γ-GTP	12	IU/l	50以下
★総コレステロール	166	183	189	★総コレステロール	194	mg/dl	130~220
★トリグリセライド	113	89	96	★トリグリセライド	83	mg/dl	35~150
★尿素窒素	12	19	17	★尿素窒素	16	mg/dl	8~21
★クレアチニン	0.7	0.8	0.7	★クレアチニン	0.7	mg/dl	0.6~1.3
★尿酸	4.0	3.7	3.7	★尿酸	3.9	mg/dl	2.0~6.5
		5.2		★Hb-A1C	4.8	%	4.3~5.8
★白血球数	79		75	★白血球数	63	×10 ⁹ /ul	36~92
★赤血球数	412	69	417	★赤血球数	409	×10 ⁴ /ul	380~500
★ヘモグロビン量	13.0	400	13.0	★ヘモグロビン量	12.7	g/dl	11.2~14.7
★ヘマトクリット値	39.2	12.8	40.0	★ヘマトクリット値	38.8	%	33.5~43.5
MCV	95	37.2	96	MCV	95	f l	81~98
MCH	31.6	93	31.2	MCH	31.1	pg	27.0~33.5
MCHC	33.2	32.0	32.5	MCHC	32.7	%	32.0~35.0
★血小板数	23.5	34.4	25.6	★血小板数	24.7	×10 ⁴ /ul	14.0~35.0
★血液像		24.8		★血液像			
骨髄球	0.0		0.0	骨髄球	0.0	%	0.0
後骨髄球	0.0	0.0	0.0	後骨髄球	0.0	%	0.0
桿状核		0.0	56.5	桿状核		%	
分葉核		4.0	9.3	分葉核		%	
好酸球	↑ 13.5	42.0	1.1	好酸球	↑ 10.6	%	1.0~5.0
好塩基球	0.9	↑ 11.0	29.0	好塩基球	0.8	%	0.0~2.0
リンパ球	30.5	1.0	0.0	リンパ球	37.0	%	27.0~53.0
異型リンパ球	0.0	39.0	4.1	異型リンパ球	0.0	%	0.0
単球	5.2	0.0		単球	6.1	%	2.0~10.0
大小不同		3.0		大小不同		%	
環状				環状		%	
奇形				奇形		%	
赤芽球				赤芽球		%	

総合報告書 I

11/04/14

11/04/28

11/05/12

総合報告書 I

11/05/26

報告 11/05/27

登録衛生検査

登録衛生検査

登録衛生検査

登録衛生検査所

メデイック

メデイック

メデイック

メデイック

大谷 敦

TEL(059)2

TEL(059)2

TEL(059)2

大谷 敦

TEL(059)224-5455

検査成績報告書

検査クリニック 3389(2377) 津健康クリニック 津健康クリニック 検 277

076

女性 29才

Final E.S. 29

11/03/03 11/03/11 11/03/31 11/04/01

定値	検査項目	測定値	測定値	単位	基準値
Serum total protein 7.3	★血清総蛋白	7.7	7.8	g/dl	6.5~8.2
Albumin 1.1	★A/G比	1.1	1.2		1.1~2.0
3.8	★アルブミン	4.1	4.2	g/dl	3.7~5.3
9.5	★ZTT	12.2	13.7	units	3.0~12.0
144	★ALP	151	156	IU/l	100~350
52	★LAP	53	52	IU/l	35~75
17	★GOT	12	15	IU/l	10~40
7	★GPT	7	9	IU/l	6~40
499	★LDH	321	301	IU/l	230~460
8	★T-GTP	8	7	IU/l	50以下
Total cholesterol 161	★総コレステロール	175	177	mg/dl	130~220
Triglyceride 72	★トリグリセライド	71	85	mg/dl	35~150
BUN 8	★尿素窒素	14	13	mg/dl	8~21
Creatinine 0.7	★クレアチニン	0.7	0.6	mg/dl	0.6~1.3
Uric acid 3.6	★尿酸	4.1	4.4	mg/dl	2.0~6.5
5.2	★Hb-A1C		4.7	%	4.3~5.8
WBC 45	★白血球数	79	75	×10 ³ /μl	36~92
RBC 496	★赤血球数	469	495	×10 ⁴ /μl	380~500
Hemoglobin 3.1	★ヘモグロビン量	12.5	13.5	g/dl	11.2~14.7
Hematocrit 41.2	★ヘマトクリット値	39.3	42.2	%	33.5~43.5
83	MCV	26.7	85	f l	81~98
26.4	MCH	31.8	27.3	pg	27.0~33.5
31.8	MCHC	43.3	32.0	%	32.0~35.0
Platelet 14.2	★血小板数	0.0	35.9	×10 ⁴ /μl	14.0~35.0
		0.0	0.0	%	0.0
		63.7	0.0	%	0.0
		2.9	58.1	%	36.0~69.0
		0.5	3.5	%	1.0~5.0
		25.7	0.5	%	0.0~2.0
		0.0	31.9	%	27.0~53.0
		7.2	0.0	%	0.0
			6.0	%	2.0~10.0

検査成績報告書

検査成績報告書

3389(2377) 津健康クリニック

3389(2377) 津健康クリニック 様

女性 29才

実施料 329点 実施料 244点

実施料 329点

コメント 11/04/14 受付 11/04/28 受付 11/05/12

コメント 11/05/27 受付 11/05/26 報告 11/05/27

検査項目	測定値	測定値	測定値
★血清総蛋白	7.5	7.6	7.4
★A/G比	1.3	1.1	1.2
★アルブミン	4.2	4.0	4.0
★ZTT	13.0	13.6	13.0
★ALP	138	148	141
★LAP	55	54	51
★GOT	14	16	16
★GPT	6	8	9
★LDH	311	357	336
★γ-GTP	7	10	9
★総コレステロール	170	174	171
★トリグリセライド	82	83	59
★尿素窒素	16	13	15
★クレアチニン	0.7	0.6	0.6
★尿酸	4.3	4.1	4.0
★白血球数	68	92	92
★赤血球数	483	69	484
★ヘモグロビン量	13.2	472	13.2
★ハマトクリット値	39.7	12.9	40.8
MCV	82	39.0	84
MCH	27.3	83	27.3
MCHC	33.2	27.3	32.4
★血小板数	30.7	33.1	31.7
★血液像		42.0	
骨髄球	0.0		0.0
後骨髄球	0.0	0.0	0.0
桿状核		0.0	61.6
分葉核		55.0	3.5
好酸球	2.6	3.9	0.3
好塩基球	0.3	0.7	28.8
リンパ球	17.8	34.3	0.0
異型リンパ球	0.0	0.0	5.8
単球	6.9	6.1	
大小不同			
環状			
奇形			
赤芽球			

検査項目	測定値	単位	基準値
★血清総蛋白	7.5	g/dl	6.5~8.2
★A/G比	1.1		1.1~2.0
★アルブミン	4.0	g/dl	3.7~5.3
★ZTT	11.8	units	3.0~12.0
★ALP	143	IU/l	100~350
★LAP	54	IU/l	35~75
★GOT	14	IU/l	10~40
★GPT	9	IU/l	6~40
★LDH	339	IU/l	230~460
★γ-GTP	7	IU/l	50以下
★総コレステロール	174	mg/dl	130~220
★トリグリセライド	93	mg/dl	35~150
★尿素窒素	14	mg/dl	8~21
★クレアチニン	0.6	mg/dl	0.6~1.3
★尿酸	4.5	mg/dl	2.0~6.5
★Hb-A1C	4.8	%	4.3~5.8
★白血球数	61	×10 ⁹ /ul	36~92
★赤血球数	484	×10 ⁴ /ul	380~500
★ヘモグロビン量	13.2	g/dl	11.2~14.7
★ハマトクリット値	40.5	%	33.5~43.5
MCV	84	f l	81~98
MCH	27.3	pg	27.0~33.5
MCHC	32.6	%	32.0~35.0
★血小板数	43.2	×10 ⁴ /ul	14.0~35.0
★血液像			
骨髄球	0.0	%	0.0
後骨髄球	0.0	%	0.0
好中球	61.1	%	36.0~69.0
好酸球	4.1	%	1.0~5.0
好塩基球	0.5	%	0.0~2.0
リンパ球	31.0	%	27.0~53.0
異型リンパ球	0.0	%	0.0
単球	3.3	%	2.0~10.0
大小不同			
環状			
奇形			
赤芽球			

総合報告書 I 11/04/14 受付 11/04/28 受付 11/05/12 総合報告書 I 受付 11/05/26 報告 11/05/27

登録衛生検査 (株)メデイック TEL(059)2 大谷 敦 登録衛生検査 (株)メデイック TEL(059)2 大谷 敦 登録衛生検査 (株)メデイック TEL(059)2 大谷 敦 登録衛生検査 (株)メデイック TEL(059)224-5455 大谷 敦

検査成績報告書

告書

告書

3389(2377)

津健康クリニック

津健康クリニック

津健康クリニック

IDNO 277

086

女性

65才

Final S.K. 65

コメント

コメント

コメント

検査

11/03/02

11/03/16

11/03/30

11/03/31

検査項目	測定値	測定値	測定値	単位	基準値
<i>Serum total protein</i> ★血清総蛋白	8.1	7.5	8.1	g/dl	6.5~8.2
★A/G比	1.4	1.3	1.3		1.1~2.0
<i>Albumin</i> ★アルブミン	4.7	4.3	4.5	g/dl	3.7~5.3
★ZTT	2.7	4.1	4.3	units	3.0~12.
★ALP	203	202	191	IU/l	100~350
★LAP	50	51	46	IU/l	35~75
★GOT	20	19	18	IU/l	10~40
★GPT	11	9	7	IU/l	6~40
★LDH	285	266	263	IU/l	230~460
★γ-GTP	15	11	10	IU/l	50以下
<i>Total cholesterol</i> ★総コレステロール	↑ 260	220	↑ 272	mg/dl	130~220
<i>Triglyceride</i> ★トリグリセライド	↑ 193	114	↑ 179	mg/dl	35~150
<i>BUN</i> ★尿素窒素	15	16	16	mg/dl	8~21
<i>Creatinine</i> ★クレアチニン	0.8	0.9	0.7	mg/dl	0.6~1.3
<i>Uric acid</i> ★尿酸	3.9	4.0	4.4	mg/dl	2.0~6.5
★Hb-A1c	5.3		5.1	%	4.3~5.8
★白血球数	53	47	46	×10 ⁴ /μl	36~92
<i>WBC</i> ★赤血球数	426	400	424	×10 ⁴ /μl	380~500
<i>RBC</i> ★ヘモグロビン量	12.5	11.7	12.6	g/dl	11.2~14.
<i>Hemoglobin</i> ★ヘマトクリット値	40.7	38.6	40.8	%	33.5~43.
<i>Hematocrit</i> MCV	96	97	96	f l	81~98
MCH	29.3	29.3	29.7	pg	27.0~33.
MCHC	↓ 30.7	↓ 15.8	↓ 30.9	%	32.0~35.
<i>Platelet</i> ★血小板数	22.5		21.7	×10 ⁴ /μl	14.0~35.
		0.0			
		0.0	0.0	%	0.0
		51.1	0.0	%	0.0
		1.5	51.6	%	36.0~69.
		1.1	2.6	%	1.0~5.1
		41.4	1.8	%	0.0~2.1
		0.0	40.7	%	27.0~53.
		4.9	0.0	%	0.0
			3.3	%	2.0~10.

総合報告書 I

11/03/02

11/03/16

11/03/30

11/03/31

登録衛生検査所

登録衛生検査所

登録衛生検査所

実施料 329

責任者

大谷 敦

(株)メディック

TEL(059)224-5455

(株)メディック

TEL(059)

(株)メディック

TEL(059)224-5455

検査成績報告書 検査成績報告 検査成績報告 検査成績報告書

津健康クリニック 津健康クリニック 3389(2377) 津健康クリニック 様
 3389(2377) 津健康クリニック [Redacted] [Redacted] [Redacted] 女性 65才

実施料 329点 実施料 244点 実施料 329点
 IDNo 2-77003 IDNo 2-77084 IDNo 2-77090
 受付 11/04/13 受付 11/04/27 受付 11/05/11 採取 11/05/25 報告 11/05/26

検査項目	測定値	測定値	測定値	検査項目	測定値	単位	基準値
*血清総蛋白	7.6	7.7	7.8	*血清総蛋白	8.1	g/dl	6.5~8.2
*A/G比	1.4	1.1	1.3	*A/G比	1.5		1.1~2.0
*アルブミン	4.4	4.1	4.4	*アルブミン	4.8	g/dl	3.7~5.3
*ZTT	3.6	4.0	4.1	*ZTT	3.6	units	3.0~12.0
*ALP	180	181	203	*ALP	200	IU/l	100~350
*LAP	49	47	50	*LAP	48	IU/l	35~75
*GOT	20	19	18	*GOT	20	IU/l	10~40
*GPT	11	9	9	*GPT	13	IU/l	6~40
*LDH	259	263	295	*LDH	292	IU/l	230~460
*γ-GTP	9	7	10	*γ-GTP	11	IU/l	50以下
*総コレステロール	228	238	251	*総コレステロール	239	mg/dl	130~220
*トリグリセライド	157	223	180	*トリグリセライド	220	mg/dl	35~150
*尿素窒素	15	18	17	*尿素窒素	14	mg/dl	8~21
*クレアチニン	0.9	0.8	0.9	*クレアチニン	0.8	mg/dl	0.6~1.3
*尿酸	4.1	3.8	4.7	*尿酸	3.8	mg/dl	2.0~6.5
		5.5		*Hb-A1C	5.1	%	4.3~5.8
*白血球数	54		44	*白血球数	42	×10 ⁹ /μl	36~92
*赤血球数	415	43	425	*赤血球数	419	×10 ⁹ /μl	380~500
*ヘモグロビン量	12.4	399	12.6	*ヘモグロビン量	12.5	g/dl	11.2~14.7
*ヘマトクリット値	39.1	11.9	40.5	*ヘマトクリット値	39.4	%	33.5~43.5
MCV	94	37.6	95	MCV	94	f l	81~98
MCH	29.9	94	29.6	MCH	29.8	pg	27.0~33.5
MCHC	31.7	29.8	31.1	MCHC	31.7	%	32.0~35.0
*血小板数	19.2	31.6	21.6	*血小板数	21.3	×10 ⁴ /μl	14.0~35.0
*血液像		19.8		*血液像			
骨髄球	0.0		0.0	骨髄球	0.0	%	0.0
後骨髄球	0.0	0.0	0.0	後骨髄球	0.0	%	0.0
好中球	54.4	0.0	56.2	好中球	53.8	%	36.0~69.0
好酸球	1.5	62.4	1.8	好酸球	1.9	%	1.0~5.0
好塩基球	0.9	1.9	1.1	好塩基球	1.2	%	0.0~2.0
リンパ球	39.5	1.2	37.5	リンパ球	37.9	%	27.0~53.0
異型リンパ球	0.0	31.7	0.0	異型リンパ球	0.0	%	0.0
単球	3.7	0.0	3.4	単球	5.2	%	2.0~10.0
大小不同		2.8		大小不同			
環状				環状			
奇形				奇形			
赤芽球				赤芽球			

4.B. IV.

**Safety Test for Long-term Administration
of Himematsutake [Iwade Strain 101][®] Powder
in Healthy Volunteers**

Hitoshi. Ito, M.D., Ph. D.
Department of Pharmacology
Mie University School of Medicine
Edobashi, Tsu, Mie 514-0001

Japan
Research Institute of Mycology and Pharmacology
1-9 Suehiro-cho, Tsu, Mie 514-0012
Japan

Shiro Suzuki, M.D., Ph.D.
Tsu Health Clinic
799-7, Kannonji-cho, Tsu, Mie, 514-0062
Japan

Introduction:

Himematsutake (official name in Japanese), *Agaricus blazei* Murrill, is an edible mushroom introduced to the late Dr. Inosuke Iwade, professor of Forest Chemistry and Applied Mushroom Science of the Faculty of Agriculture, Mie University, Japan in 1965. Prof. Iwade founded a company named Iwade Research Institute of Mycology to analyze mushrooms chemically and conduct study about ingredients of mushrooms. In 1975, Iwade Research Institute of Mycology, with tremendous efforts by its staffs, succeeded in artificial cultivation of Himematsutake for the first time in the world.

With extensive study on Himematsutake led by Dr. Hitoshi Ito at Department of Pharmacology, Mie University School of Medicine, Japan, the research team discovered Himematsutake's strong antitumor effects. Then they identified one strain, which marked the highest antitumor effects, and named it "Himematsutake [Iwade Strain 101][®]".

Himematsutake [Iwade Strain 101][®] and its antitumor effects were tested on numbers of experiments and reported to the academic and scientific associations and meetings. In 1980, the research on antitumor effects of Himematsutake [Iwade Strain 101][®] was officially introduced to the 39th Annual Meeting of the Japanese Cancer Association and the 54th General Meeting of Japanese Pharmacological Society. Since then, the research has been continuously conducted and reported to the reputable meetings. The discovery of antitumor effects of Himematsutake [Iwade Strain 101][®] and its effectiveness on tumor-implanted mice captured tremendous people's attention and was exposed on mass mediums such as TV, newspapers and magazines in Japan.

Iwade Research Institute of Mycology established mass production of the mushroom in 1983. Over 10,000 people who tend to be cancer patients have administered the Himematsutake [Iwade Strain 101][®] products in a form of dried, powder and granule. They usually take the amount of the product that is equivalent to 5g - 50g of fruiting body of dried mushroom per day. There has been no report of side effect for long-term administration of the products. Therefore, it is conceived that the Himematsutake [Iwade Strain 101][®] products are the extremely safe edible mushroom.

In this report, the healthy volunteers, who agreed to cooperate with the theme of this study, were tested, with an open & trial method, to determine if the Himematsutake [Iwade Strain 101][®] powder would be safe for long-term administration and/or there would be any side effect. The following is the report of the trial:

I. Material Sample:

The material sample, Himematsutake [Iwade Strain 101][®] Powder was provided by Iwade Research Institute of Mycology at 1-9 Suehiro-cho, Tsu, Mie 514-0012, Japan.

Chemical Specifications of Himematsutake [Iwade Strain 101]® Powder:

Energy	Kcal/100g	350
Water Content	g/100g	1.2
Crude Ash	g/100g	1.2
Crude Protein	g/100g	7.0
Crude Fat	g/100g	0.6
Crude Fiber	g/100g	0.9
Total Sugar	g/100g	19.1
GS Fiber	g/100g	70.0

Remarks: 1 pack contains 5 g of Himematsutake [Iwade Strain 101]® Powder

II. Subject:

The subjects were 20 male and 15 female university students ranging in age from 19 to 23.

III. Methods and Terms of Administration:

For male, 30g (6 packs) of Himematsutake [Iwade Strain 101]® Powder per day, 2 packs after every meal - 3 times a day, were given for administration. For female, 15g (3 packs), 1 pack after every meal - 3 times a day, were given for administration.

The term of administration was for a period of 6 months.

Remarks:

- Originally, there were 25 male and 19 female subjects. However, 5 male and 3 female, who went back to their home town during the summer and winter vacation and stopped taking Himematsutake [Iwade Strain 101]® Powder, were excluded from the trial. Also, 1 female, who had other medication during the term was excluded as well.
- Double blind test was not proceeded for this trial.

IV. Clinical Test Items:

WBC, RBC, Hb, Hct, MCV, MCH, MCHC, Platelet, GOT, GPT, T-Chol., Triglyceride, HDL-C and Uric Acid were tested monthly on each subject for a period of 6 months. Each subject wrote down any signs and changes of her physical conditions on the questionnaire.

V. Result of Clinical Test:

The result was compared between male and female. As it is shown, the figures on RBC, Hb, Hct and Uric Acid for female were relatively lower than the ones for male. However, the figures were still all in a normal range.

There was no significant change on WBC, MCV, MCH, MCHC, Platelet, GOT, GPT, T-Chol., Triglyceride and HDL-C.

VI. Result of Subjective Signs and Improvement:

The result of subjective signs and improvement indicated on Table 3 & 4 were all claimed by the subjects.

Table 3 - Subjective Signs after taking Himematsutake [Iwade Strain 101]® Powder for 20 male subjects

Subjective Signs		Before		1 month after		3 months after		6 months after	
		No.	%	No.	%	No.	%	No.	%
Appetite	(-)	3	15	1	5	0	0	0	0
	(±)	9	45	6	30	5	25	3	15
	(+)	8	40	13	65	15	75	17	85
Digestion	(-)	11	55	16	80	14	70	15	75
	(±)	6	30	4	20	6	30	5	25
	(+)	3	15	0	0	0	0	0	0
Stool (amount)	(-)	2	10	0	0	0	0	0	0
	(±)	13	65	5	25	6	30	6	30
	(+)	5	25	15	75	14	70	14	70
Urine (amount)	(-)	0	0	0	0	0	0	0	0
	(±)	13	65	8	40	7	35	6	30
	(+)	7	35	12	60	13	65	14	70
General Condition	(-)	2	10	0	0	0	0	0	0
	(±)	7	35	6	30	6	30	6	30
	(+)	11	55	14	70	14	70	14	70

Table 4 - Subjective Signs after taking Himematsutake [Iwade Strain 101]® Powder for 15 female subjects

Subjective Signs		Before		1 month after		3 months after		6 months after	
		No.	%	No.	%	No.	%	No.	%
Appetite	(-)	5	33	3	20	1	7	1	7
	(±)	10	67	2	13	1	7	1	7
	(+)	0	0	10	67	13	87	13	87
Digestion	(-)	10	67	12	80	13	87	15	100
	(±)	3	20	2	13	2	13	0	0
	(+)	2	13	1	7	0	0	0	0
Stool (amount)	(-)	4	27	0	0	1	7	0	0
	(±)	8	53	4	27	2	13	3	20
	(+)	3	20	11	73	12	80	12	80
Urine (amount)	(-)	1	7	0	0	0	0	0	0
	(±)	12	80	6	40	5	33	4	27
	(+)	2	13	9	60	10	67	11	73
General Condition	(-)	3	20	0	0	0	0	0	0
	(±)	8	53	11	73	10	67	8	53
	(+)	4	27	4	27	5	33	7	47

VII. Side Effect:

There was no significant side effect observed or claimed. 2 male and 1 female subjects expressed that they did not prefer the taste and smell of the mushroom. However, the preference on the taste and smell of the mushroom varies depending on the person. Also, this point is referred to other edible mushrooms, and therefore, shall not be necessarily considered.

VIII. Conclusion:

The 20 male subjects consumed 30g and 15 female subjects consumed 15g of Himematsutake [Iwade Strain 101]® Powder per day for a period of 6 months. As a result, no hematological and biochemical abnormality were found in the subjects. On the other hand, subjective improvements such as smoothie and larger amount of evacuation and urination, and better sight, increased after 2 weeks of administration. With these in mind, it is conceived that Himematsutake [Iwade Strain 101]® Powder is safe for long-term administration and has no side effect.

Table.1 Changes of hematological and Biochemical findings in healthy volunteers treated orally with 30 g of Himematsutake Powder for 6 months

Case No. 1~20

Age : between the ages of 19 and 23

Sex : male

Month	Case No.	Normal range	n = 20	n = 20	n = 19	n = 20	n = 18	n = 20	n = 20
			0	1	2	3	4	5	6
WBC ($\times 10^2 / \mu l$)		36~92	71.2 \pm 10.1	71.4 \pm 12.3	73.7 \pm 9.7	72.3 \pm 11.6	73.1 \pm 11.8	72.0 \pm 9.7	72.8 \pm 10.5
RBC ($\times 10^4 / \mu l$)		420~560	470 \pm 20.2	489 \pm 25.6	494 \pm 30.7	521 \pm 26.9	511 \pm 33.1	498 \pm 24.6	511 \pm 25.8
Hb (g/dl)		13.0~17.0	16.2 \pm 0.51	16.4 \pm 1.57	15.7 \pm 0.46	16.3 \pm 1.63	16.1 \pm 1.10	15.8 \pm 0.56	16.0 \pm 0.89
Hct (%)		39.0~50.0	43 \pm 1.3	44 \pm 2.1	43 \pm 1.8	44 \pm 1.5	44 \pm 1.7	46 \pm 1.8	45 \pm 1.9
MCV (fl)		81~98	86.1 \pm 1.17	83.4 \pm 2.34	85.7 \pm 2.98	89.1 \pm 3.31	90.4 \pm 3.26	85.9 \pm 3.91	86.2 \pm 3.11
MCH (pg)		27.0~33.5	27.4 \pm 0.69	28.4 \pm 0.93	27.9 \pm 1.50	29.8 \pm 1.45	29.9 \pm 1.30	30.2 \pm 1.89	28.2 \pm 1.52
MCHC (%)		32.0~35.0	34.3 \pm 0.65	35.0 \pm 0.59	34.7 \pm 0.89	34.9 \pm 0.64	32.8 \pm 0.75	33.6 \pm 0.71	34.1 \pm 0.78
Plt ($\times 10^4 / \mu l$)		14.0~35.0	24.6 \pm 1.21	25.5 \pm 1.00	25.3 \pm 1.73	26.7 \pm 2.53	27.9 \pm 2.70	28.4 \pm 3.43	27.0 \pm 3.78
GOT (IU/l)		10~40	30 \pm 2.9	27 \pm 4.1	29 \pm 3.2	32 \pm 3.7	31 \pm 2.8	28 \pm 2.6	30 \pm 3.6
GPT (IU/l)		3~30	16 \pm 1.8	13 \pm 2.0	14 \pm 2.6	20 \pm 6.9	21 \pm 5.5	19 \pm 2.3	17 \pm 2.9
T-CHO (mg/dl)		120~240	139 \pm 14.3	142 \pm 11.8	131 \pm 12.9	132 \pm 17.6	147 \pm 12.7	141 \pm 14.5	136 \pm 15.2
TG (mg/dl)		40~170	97 \pm 18.1	93 \pm 23.9	101 \pm 37.1	119 \pm 31.5	116 \pm 28.2	120 \pm 25.1	124 \pm 39.3
HDL-C (mg/dl)		30~75	51 \pm 8.2	48 \pm 10.1	47 \pm 9.3	48 \pm 6.9	56 \pm 5.8	42 \pm 9.5	50 \pm 12.8
Uric acid (mg/dl)		2.5~7.5	4.4 \pm 0.57	4.2 \pm 0.40	4.1 \pm 0.49	4.5 \pm 1.28	4.0 \pm 0.63	4.9 \pm 1.10	4.7 \pm 1.33

Values are expressed as means \pm S.E.

Table. 2 Changes of hematological and Biochemical findings in healthy volunteers treated orally with 15 g of Himematsutake Powder for 6 months

Case No. 21~35

Age : between the ages of 19 and 23

Sex : female

Case No.	Normal range	n = 15	n = 15	n = 15	n = 15	n = 13	n = 13	n = 15
Month		0	1	2	3	4	5	6
WBC ($\times 10^2/\mu l$)	36~92	69.3 \pm 10.9	71.0 \pm 11.5	72.3 \pm 11.4	71.5 \pm 9.7	72.0 \pm 12.5	71.3 \pm 9.8	73.4 \pm 8.7
RBC ($\times 10^4/\mu l$)	420~560	452 \pm 22.3	479 \pm 28.2	486 \pm 29.1	473 \pm 24.7	463 \pm 19.8	468 \pm 23.3	479 \pm 24.4
Hb (g/dl)	13.0~17.0	14.6 \pm 0.32	14.4 \pm 0.54	15.0 \pm 1.17	15.7 \pm 0.93	15.4 \pm 0.67	15.5 \pm 0.57	15.4 \pm 0.79
Hct (%)	39.0~50.0	40 \pm 1.4	42 \pm 1.9	41 \pm 1.8	43 \pm 2.0	42 \pm 2.1	41 \pm 1.3	40 \pm 1.5
MCV (fl)	81~98	81.4 \pm 2.23	84.9 \pm 1.71	84.2 \pm 2.11	83.6 \pm 1.91	83.5 \pm 1.85	85.5 \pm 2.24	83.1 \pm 1.76
MCH (pg)	27.0~33.5	28.5 \pm 0.72	26.9 \pm 0.77	26.9 \pm 0.81	29.0 \pm 0.94	29.2 \pm 0.98	28.7 \pm 0.85	27.4 \pm 0.74
MCHC (%)	32.0~35.0	33.4 \pm 0.84	34.1 \pm 0.92	34.6 \pm 0.99	33.8 \pm 0.78	35.0 \pm 1.21	34.7 \pm 0.95	33.6 \pm 1.00
Plt ($\times 10^4/\mu l$)	14.0~35.0	23.6 \pm 1.53	23.1 \pm 0.84	25.9 \pm 1.72	23.8 \pm 1.37	25.8 \pm 2.64	26.0 \pm 1.94	25.4 \pm 1.30
GOT (IU/l)	10~40	29 \pm 2.3	24 \pm 5.1	22 \pm 8.7	26 \pm 5.7	22 \pm 3.5	24 \pm 4.1	23 \pm 3.6
GPT (IU/l)	3~30	22 \pm 2.7	22 \pm 2.9	18 \pm 1.9	20 \pm 2.3	19 \pm 2.8	22 \pm 1.8	19 \pm 2.1
T-CHO (mg/dl)	120~240	132 \pm 18.2	139 \pm 15.3	133 \pm 17.9	141 \pm 27.7	149 \pm 20.3	138 \pm 29.1	135 \pm 26.4
TG (mg/dl)	40~170	107 \pm 29.1	103 \pm 23.6	111 \pm 46.2	128 \pm 60.3	125 \pm 40.2	112 \pm 31.7	124 \pm 28.6
HDL-C (mg/dl)	30~75	50 \pm 9.6	53 \pm 6.4	52 \pm 7.6	58 \pm 8.2	54 \pm 6.5	56 \pm 7.2	62 \pm 9.8
Uric acid (mg/dl)	2.5~7.5	3.2 \pm 0.95	3.5 \pm 0.91	4.0 \pm 0.54	3.6 \pm 0.93	3.4 \pm 0.66	3.3 \pm 1.01	3.4 \pm 0.74

Values are expressed as means \pm S.E.

4.B. V.

Clinical Trial with Himematsutake [Iwade Strain 101][®] Powder

on Patients with Malignant Tumor

(Study on Long-term Administration and Side Effect)

Shiro Suzuki, M.D., Ph.D.
Tsu Health Clinic
799-7, Kannonji-cho, Tsu, Mie, 514-0062
Japan

Hitoshi. Ito, M.D., Ph. D.
Department of Pharmacology
Mie University School of Medicine
Edobashi, Tsu, Mie 514-0001
Japan
Research Institute of Mycology and Pharmacology
1-9 Suehiro-cho, Tsu, Mie 514-0012
Japan

Introduction:

In recent years, chemotherapy and immunotherapy have been taking a big role on cancer treatment, and numbers of clinical cases for those methods greatly increased around the globe. On the other hand, Himematsutake (official name in Japan), one of edible mushrooms - scientific name: *Agaricus blazei* Murrill, has captured great attention from an immunotherapy field of view.

During this trial, we had an opportunity to review Himematsutake [Iwade Strain 101]® Powder on patients with malignant tumor to determine if the product would be safe for long-term administration and/or there would be any side effect. The following is the report of the clinical trial:

I. Material:

"Himematsutake [Iwade Strain 101]® Powder" was provided by Iwade Research Institute of Mycology Co., Ltd. at 1-9 Suehiro-cho, Tsu, Mie 514-0012, Japan.

Chemical Specifications of Himematsutake [Iwade Strain 101]® Powder:

Energy	kcal/100g	350
Water Content	g/100g	1.2
Crude Ash	g/100g	1.2
Crude Protein	g/100g	7.0
Crude Fat	g/100g	0.6
Crude Fiber	g/100g	0.9
Total Sugar	g/100g	19.1
GS Fiber	g/100g	70.0

Remarks: 1 pack contains 5 g of Himematsutake [Iwade Strain 101]® Powder

II. Subject Patients: (see Table 1)

Name of diagnosed cancer:

- | | | |
|----|-------------------------------|----------------|
| 1) | 1 case of uterine sarcoma | |
| 2) | 2 case of ovarian tumor | |
| 3) | 7 cases of cervical carcinoma | Total 10 cases |

Type of cancer:

- | | |
|----|------------------------------------|
| 1) | 2 cases of cystadenoma |
| 2) | 7 cases of squamous cell carcinoma |
| 3) | 1 case of sarcoma |

III. Treatment Methods

Each patient (except cases No.9 and 10) previously had a surgical operation before taking Himematsutake [Iwade Strain 101][®] Powder. 2 packs-10g of Himematsutake [Iwade Strain 101][®] Powder was given to each patient 3 times a day before every meal.

The total intake amount of Himematsutake [Iwade Strain 101][®] Powder per person was between 3,360g (case No.1: 112days) and 10,860g (case No.5: 362days).

IV. Terms:

The term of administration was between 112 days and 362 days.

V. Other Conditions:

1 case had 5-FU treatment, 10mg/kg once a week for 10 consecutive weeks, before taking Himematsutake [Iwade Strain 101][®] Powder.

In case of radiation therapy, Linac 6MV x-ray, ⁶⁰Co- γ -ray was given for 3 weeks, 200 rad per day, 1000 rad per week.

VI. Clinical Test Items:

- 1) Blood Test: RBC, Hemoglobin, Hematocrit, WBC, Platelet, Total Protein, Albamin/Globumin Ratio, γ -globulin, GOT, GPT
- 2) Delayed Skin Test (PPD): An intradermal injection of PPD - 0.05 μ g/0.1ml was given. The test result was conducted 48 hours after the injection. The average of vertical and horizontal lengths of erythema was measured.

PPD - manufactured by Japan BCG

- 3) Intradermal PHA Test: An intradermal injection of the purified PHA - 5 μ g/0.1ml was given. The test result was conducted 24 hours after the injection. The average value of vertical and horizontal lengths of erythema was measured.

Purified PHA - manufactured by Wellcome

- 4) Lymphocytes: Lymphocytes count in peripheral blood was measured by Hamatrak 360 Automated Differential System.

Hamatrak 360 Automated Differential System - manufactured by Geometrac

* As for NK cell, used Flow Cytometry method for measurement

Flow Cytometry - Becton Dickinson

- VII. Results:** (see Fig. 1 ~ 14)
- 1) RBC: (see Fig. 1)
There was no significant change. Instead, there was a tendency of increase.
 - 2) Hemoglobin: (see Fig. 2)
There was no significant change.
 - 3) Hematocrit: (see Fig.3)
No depression of hematocrit was observed.
 - 4) WBC: (see Fig. 4)
The changes of WBC were observed, but there was no decrease.
 - 5) Lymphocytes: (see Fig. 5)
Lymphocytes count was shown on the diagram as an index of immunotherapy. As the term of intake goes longer, lymphocytes count increased.
 - 6) Platelet: (see Fig. 6)
There were slight changes, but no major changes were observed
 - 7) Total Protein: (see Fig. 7)
There were slight changes, but no decrease was observed
 - 8) Albumin/Globulin Ratio (see Fig. 8)
Observed a significant increase on case No. 9.
 - 9) γ -globulin: (see Fig. 9)
Observed no significant change.
 - 10) GOT: (see Fig. 10)
Observed remarkable depression on case No. 3, 9 and 10 whose GOT was high before taking Himematsutake [Iwade Strain 101][®] Powder.
 - 11) GPT: (see Fig. 11)
Observed depression on case No. 3, 9 and 10 whose GPT was relatively high before taking Himematsutake [Iwade Strain 101][®] Powder.

● Observed no abnormal indication of GOT and GPT on all the subject patients after taking Himematsutake [Iwade Strain 101][®] Powder.

12) PPD Response:

(see Fig. 12)

Erythma (mm)	Before n=10	After 3M n=10	After 6M n=8
0 - 9 (-)	2	0	0
10 - 19 (+)	4	3	2
20 > (++)	4	7	6

Observed positive PPD Response on each subject patients. 2 subject patients marked negative PPD Response before taking Himematsutake [Iwade Strain 101]® Powder, but turned to be positive (+ & ++) after taking it. As a result, all 6 subject patients notably increased their PPD Response even more toward positive after taking it.

13) PHA Response:

(see Fig. 13)

Tested PHA Response on 6 subject patients - case No. 1, 2, 3, 7, 8 and 9 whose mean diameter of erythema was less than 20 mm on PPD Response.

2 out of 6 subject patients marked negative PHA Response when started taking Himematsutake [Iwade Strain 101]® Powder, but turned to be positive after taking it. As a result, all 6 subject patients, except No. 8, notably increased their PHA Response even more toward positive after taking it.

14) NK cell Response

(see Fig. 14)

Tested NK cell Response on 6 subject patients - case No. 1, 2, 3, 7, 8, and 9. 2 out of 6 subject patients marked less than 10% of NK cell in peripheral blood while the normal range is 18% - 40%. After taking Himematsutake [Iwade Strain 101]® Powder, observed the remarkable increase of NK cell activity on all 6 subject patients.

VIII. Confirmed Benefits from Clinical Trial:

It is a common practice and procedure to evaluate this type of clinical trial without controlled subjects.

However, after 2 weeks of administration, all 10 subject patients experienced and confirmed the self-defined common physical changes such as improvements on general physical condition, taste better in food, hold tenseness on tummy, smooth stool and so on.

As far as the long-term administration is concerned, there was no side effect observed on 10 subject patients throughout the trial. As they took Himematsutake [Iwade Strain 101]® Powder for a longer period, clearly observed that they looked well and improved their skin condition.

IX. Conclusion:

- 1) As shown in the result of PPD and PHA Skin Test, it was confirmed that the immune system of all the subject patients (except case No. 8 in PHA skin test) was strengthened by the administration of Himematsutake [Iwade Strain 101][®] Powder. This result shall support the result of the animal experiment, which was conducted previously. (see References 1-4)
- 2) As it is shown in the result, the trend of improvement on Lymphocytes count and NK cell activity were seen. This result shall support the result of the animal experiment, which was conducted previously.

* Based on the above 1) & 2), it is certain that Himematsutake [Iwade Strain 101][®] Powder promotes cellular immunity response.
- 3) For those who had the high figures in GOT and GPT encountered the trend of decrease in them as indicated in the test result.
- 4) RBC was not significantly changed, but rather increased in a certain degree.
- 5) Even after the long-term administration, WBC remained within a normal range, and did not encounter any decrease during the trial.
- 6) Hemoglobin, hematocrit, platelet, total protein, A/G ratio and γ -globulin were all within a normal range during the trial

Based on the result from the trial, it is concluded that Himematsutake [Iwade Strain 101][®] Powder is safe for long-term oral administration and causes no side effect. Furthermore, Himematsutake [Iwade Strain 101][®] Powder can be the optimum adjuvant immunochemotherapy for a long-term use together with the series of treatment of surgical operation, chemotherapy and/or radiotherapy.

References:

- 1) Shimura K, Ito H and Hibasami H: Screening of host-mediated antitumor polysaccharides by crossed immunoelectrophoresis using fresh human serum, *Jpn J Pharmacol* 33, 403-408 (1983)
- 2) Itoh H, Ito H, Amano H and Noda H: Inhibitory action of a (1→6)- β -D-glucan-protein complex (F III-2-b) isolated from *Agaricus blazei* Murill ("Himematsutake") on Meth A fibrosarcoma-bearing mice and its antitumor mechanism. *Jpn J Pharmacol* 66, 265-271 (1994)
- 3) Ito H, Shimura K, Itoh H and Kawade H: Anti-tumor effects of a new polysaccharide-protein complex (ATOM) prepared from *Agaricus blazei* (Iwade Strain 101) "Himematsutake" and its mechanisms in tumor-bearing mice. *Anticancer Res* 17, 277-284 (1997)
- 4) Ito H: New Initiatives in Mycological Research Proceedings of the Third International Symposium of the Mycological Society of Japan. pp. 11-16 (1995)

Table. 1 Oral administration of Himematsutake [Iwade Strain 101][®] Powder on patients with malignant tumor

Cases No.	Age	Diagnosis	Treatment prior to Himematsutake [Iwade Strain 101] [®] Powder			Treatment* (days)	Outcome after use
			chemotherapy	radition	surgical		
1	51	ut. Sarcoma	5-FU		ope	112	alive
2	48	OV. K1 (Cystadenoma)		Linac	ope	185	alive
3	53	OV. K (Cystadenoma)			ope	123	alive
4	49	C.C. I b (Squamous cell carcinoma)		Linac	ope	265	alive (rest)
5	59	C.C. II b (Squamous cell carcinoma)		Co	ope	362	alive (rest)
6	57	C.C. I b (Squamous cell carcinoma)		Co	ope	195	alive
7	40	C.C. II b (Squamous cell carcinoma)		Linac	ope	202	alive (recur)
8	62	C.C. II b (Squamous cell carcinoma)		Linac	ope	219	alive (rest)
9	41	C.C. I b (Squamous cell carcinoma)				227	alive
10	56	C.C. I b (Squamous cell carcinoma)		Linac		190	alive

* Himematutake [Iwade Strain 101][®] Powder was given a certain period oral administration from 5-7 days after surgical operation




Fig. 1. RBC (red blood cell) count




Fig. 2. Hb (hemoglobin)




Fig. 3. Hct (hematocrit)




Fig. 4. WBC (white blood cell) count




Fig. 5. Lymphocytes




Fig. 6. Platelet




Fig. 7. Total Protein




Fig. 8. A/G ratio




Fig. 9. γ -globulin




Fig. 10. GOT




Fig. 11. GPT




Fig. 12. Changes of PPD responses after treatment with Himematsutake Powder




Fig. 13. Changes of PHA responses after treatment with Himematsutake Powder




Fig. 14. Changes of NK cell responses after treatment with Himematsutake Powder

4.B. VI.

4.B.VI.

Revised Product specifications of
Himematsutake Powder
(CONFIDENTIAL)